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Abstract
Combinations of metabolic blockers (including fenofibrate) with chemotherapeutic
drugs interfere with the drug-resistance of prostate cancer cells. However, their
effect on cancer stem cells-dependent microevolution of prostate cancer malignancy
remains unaddressed. Here, we hypothesize that the combined docetaxel/fenofibrate
treatment prompts the selective expansion of cancer stem cells that affects the
microevolution of their progenies. Accordingly, we adapted a combined in vitro/
in vivo approach to identify biological and therapeutic consequences of this process.
Minute subpopulations of docetaxel-resistant CD133high and/or CD44high cancer
stem cell-like (SCL) cells were found in prostate cancer DU145 and PC3 cell
populations. When pretreated with docetaxel, they readily differentiated into
docetaxel-resistant CD44negative “bulk” cells, thus accounting for the microevolution
of drug-resistant cell lineages. Combined docetaxel/fenofibrate treatment induced
the generation of poly(morpho)nuclear giant cells and drug-resistant CD44high SCL
cells. However, the CD44negative offspring of docetaxel- and docetaxel/fenofibrate-
treated SCLs remained relatively sensitive to the combined treatment, while retaining
enhanced resistance to docetaxel. Long-term propagation of drug-resistant SCL-
derived lineages in the absence of docetaxel/fenofibrate resulted in their reverse
microevolution toward the drug-sensitivity and invasive phenotype. Consequently,
prostate tumors were able to recover from the combined docetaxel/fenofibrate
stress after the initial arrest of their expansion in vivo. In conclusion, we have con-
firmed the potential of fenofibrate for the metronomic treatment of drug-resistant
prostate tumors. However, docetaxel/fenofibrate-induced selective expansion of
hyper-resistant CD44high SCL prostate cells and their “bulk” progenies prompts the
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microevolution of prostate tumor drug-resistance. This process can limit the imple-
mentation of metabolic chemotherapy in prostate cancer treatment.
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1 | INTRODUCTION
Tumor homeostasis and development is governed by minute (<1%)
populations of multipotent cells (cancer stem cells [CSCs]).1,2 CSCs
can evolve from transformed tissue-specific stem cells. Alternatively,
they originate from the “bulk” cancer cells in the process of “retro-
differentiation,” which can be triggered by genetic/epigenetic aberra-
tions and/or by aberrant intratumoral communication systems.3
Because of their self-renewal capacity and multipotency, CSCs reside
at the top of hierarchy of tumor cell phenotypes and give rise to inter-
mediate progenitors and terminally differentiated progeny.4,5 Thus,
they participate in the phenotypic plasticity and diversity of cancer
cell populations.4,6 Furthermore, the activity of DNA repair systems
and membrane efflux pumps, accompanied by relative dormancy of
CSCs, accounts for their high drug-resistance.7,8 Consequently, CSC
abundance increases during tumor treatment. These features account
for the adaptability of tumors to the extrinsic stress.4,9 As its conse-
quence, premature cessation of chemotherapy commonly results in an
expansion of drug-resistant CSCs and their progenies in prostate
tumors.10 These cells subsequently rebuild the prostate tumor and
other tumors in the more malignant form.11-14
Prostate cancer is one of the most frequently diagnosed cancers
and the second leading cause of cancer-related deaths in Euro-
American populations.15 Its latency period is relatively long; however
the risk of prostate tumor formation increases with the age of the
patient. Conventional strategies of prostate cancer treatment (surgical
intervention, chemotherapy, and androgen ablation) usually provide a
temporary symptom relief but hardly interfere with the cancer pro-
gression. Usually, they also prompt the microevolution of tumor drug
resistance, enforcing the intensification of chemotherapy against con-
tinuously more aggressive tumor within the weakening organism of
the patient.13 Harmful effects of this vicious cycle are of particular
importance for the palliative/elderly patients, who are oversensitive
to the adverse effects of chemotherapeutics.16 These effects enforce
premature treatment cessations that facilitate tumor recurrence and
its metastatic cascade. “Clonal evolution” and activation of the dor-
mant, drug-resistant, phenotypically plastic, and multipotent
CSCs3,17,18 participates in this process and ultimately leads to abrupt
tumor relapses.
CSCs are routinely distinguished on the basis of stem surface and
intracellular stem cell markers: CD44, CD133, Oct3/4, Sox2, Klf4,
Nanog, etc.13 Their presence is commonly observed in the biopsies
from prostate tumors.13,17,19 Like other CSCs, prostate CSCs possess
self-renewal capacity and genetic/epigenetic/phenotypic plasticity
that prompt them to drive tumor microevolution and metastatic dis-
semination in response to the signals from niche.14,19-21 The activa-
tion of CSCs in prostate tumors under chemotherapeutic stress has
particularly dreadful consequences for prostate cancer patients. A nar-
row window between patient's collapse and cancer relapse poses a
crucial limitation for prostate cancer chemotherapy. Accordingly, new
regimens are required that would reduce the effective doses of che-
motherapeutics, while preventing the CSC-dependent microevolution
of prostate tumor drug resistance.
Metronomic therapies based on the combined application of
cytostatic drugs and metabolic blockers can potentially interfere with
the progression of drug-resistant prostate tumors, concomitantly
exerting less intense systemic adverse effects than conventional ther-
apies. We have recently shown that fenofibrate (FF)-based metro-
nomic regimens interfere with the drug resistance and malignancy of
prostate cancer cells, while reducing adverse effects of chemothera-
peutics.22 FF is commonly used to improve high:low-density lipopro-
tein ratio in hyperlipidemia.23 The peroxisome-proliferator activated
receptor-α and reactive oxygen species-dependent signaling systems
“canonically” mediate its biological activity.24 They also account for its
anticancer properties.25,26 Interference of FF with cancer cell expan-
sion and systemic dissipation27 is accompanied by its effects on can-
cer “stroma,” including vascular cells,24,28 and cellular energy
metabolism.22,29,30 Thus, FF interferes with drug-resistance systems
and sensitizes drug-resistant prostate cancer cells to chemotherapy.
Significance statement
Fenofibrate has recently been shown to interfere with
the drug resistance of prostate tumor cells. The data of
this study confirmed that fenofibrate increases sensitivity
of drug-resistant prostate tumors to chemotherapeutic
stress. However, the data also revealed the resistance of
CD44+ prostate cancer stem cells to the combined doce-
taxel/fenofibrate treatment, accompanied by docetaxel/
fenofibrate-induced microevolution of hyper-resistant
CD44− progenies. Thus, the balance between the sensi-
tivity of CD44low prostate cancer cells to chemothera-
peutics and the adaptation of CD44high stem-like cells to
metabolic stress determines the response of prostate
tumors to metabolic chemotherapy.
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Along with its systemic tolerability, these facts justify FF application
in the palliative treatment of malignant prostate tumors. However, its
effect on CSC-related microevolution of drug-resistant tumors
remains unknown.
CD133+/CD44+ cells are commonly present within prostate
tumors in vivo.13,17,19 Even though a full “stem cell” signature of CSCs
in vitro is still the matter of debate,18,31 CD133+ and/or CD44+ cancer
stem cell-like (SCL) cells have been observed in prostate cancer cell
DU145 and PC3 lines in vitro.32,33 Thus, they imitate the hierarchical
structure of prostate tumors, providing a tool for the identification of
processes that underlie their clonal expansion under chemotherapeu-
tic/metabolic stress in vivo. Here, we hypothesized that the combined
docetaxel (DCX)/FF treatment can prompt the clonal evolution of
CSC/SCL cells. Accordingly, we adapted a combined in vitro/in vivo
approach to identify biological and therapeutic consequences of this
activity. We estimated the effect of the combined DCX/FF treatment
on the phenotypic microevolution of prostate cancer cell populations.
In particular, we focused (a) on the pattern of clonal expansion of
CD44+ DU145/PC3 SCL cells under DCX and/or FF stress, (b) on the
phenotype of their CD44− “bulk” progeny, and (c) on the interference
of FF with the chemoresistance pattern and invasiveness of CD44−
“bulk” cells.
2 | MATERIALS AND METHODS
2.1 | Cell cultures, preselection, and
fluorescence-activated cell sorting
Human prostate carcinoma DU145 (ATCC; HTB81), PC3 cells (ATCC;
CRL1435), and their SCL-derived offspring (see below) were routinely
cultivated in Dulbecco' modified Eagle's Medium/F12 HAM medium
supplemented with 10% FBS and antibiotics (Sigma, St. Louis, Mis-
souri).24,34 For endpoint experiments, media supplemented with doce-
taxel (DCX; 0.125-50 nM, Sigma) and FF (5-25 μM; F6020, Sigma)
were added to cancer cell cultures at the concentrations given in the
text. For the isolation of CD44+/CD133+ subpopulations, the cells were
cultivated in the presence of DCX (10 nM) and/or FF (25 μM) for
48 hours, dissociated with 1 mM EDTA in Ca++/Mg++-free PBS,
suspended in culture medium, centrifuged/washed in Ca++/Mg++-free
PBS and incubated in mouse phycoerythrin-conjugated anti-CD133
IgG/mouse fluorescein isothiocyanate-conjugated anti-CD44 IgG
(1:100) solution for 30 minutes. After washing, CD44high and/or
CD133high cells were sorted out with fluorescence-activated cell sorter
(FACS) Aria (BD Systems, Heidelberg, Germany), using 488/512 nm
excitation and a 525BP(FL1)/575LP(FL2) emission filter sets, or with
ImageStreamX system (Amnis). For each analysis, 107 cells were initially
identified according to a particle diameter exceeding 8 μm.
Microevolution of multi-drug resistance in DU145/PC3 cell
populations was prompted by the intermittent cell exposition to DCX
administered at the increasing concentrations (0.5-50 nM).22 Shortly,
the cells were cultivated for 3 days in DCX (0.5 nM)-containing
medium, followed by 72 hours of incubation in the pure medium
containing 30% of DU145-conditioned medium, before the next
round of DCX treatment. After 3 cycles of treatment/recovery, the
procedure was repeated in the presence of 1, 2, 5, 10, 20, and 50 nM
DCX. The established cell lineages were cultivated in standard
medium and repeatedly subjected to pulse 20/50 nM DCX treatment
to sustain drug-resistance in short-term (ST) populations. Concomi-
tantly, established lineages were maintained in standard DCX-free
medium for at least 30 passages (1:8) to obtain drug-sensitive long-
term (LT) variants. SCL-derived, drug-resistant DU145/PC3 cells
between 5th and 15th passage after the lineage establishment were
used in the experiments. Stability of their acquired phenotype was
assessed after freezing/thawing and following drug withdrawal
throughout this period. Untreated parental cells were cultivated
alongside.
2.2 | Immunofluorescence
For the immunofluorescence studies of Oct-4, Nanog, and CD44, the
cells were fixed with methanol:acetone (7:3, −20C) for 15 minutes.
α-Tubulin and vinculin were visualized in the cells that had been fixed
with formaldehyde (3.7%; 20 minutes in RT) and permeabilized with
Triton X-100 (0.1%; 10 minutes in RT). Primary antibodies: mouse
anti-Oct3/4 IgG, mouse anti-CD44 IgG, rabbit anti-Nanog IgG, rabbit
anti-vinculin IgG, and mouse anti-α-tubulin IgG (all from Sigma) were
applied for 1 hour, immediately after the incubation in the presence
of 3% BSA. Then, the cells were labeled with Alexa 488-conjugated
goat anti-mouse IgG and/or Alexa 488-conjugated goat anti-rabbit
IgG (No. A11001 and A11008, Invitrogen, Carlsbad, California). When
indicated, the cells were counterstained with TRITC-conjugated
phalloidin (No. 77418, Sigma) and Hoechst 33258 (No. B2883,
Sigma).34 Image acquisition was performed with a Leica DMI6000B
microscope (DMI7000 version; Leica Microsystems, Wetzlar,
Germany) equipped with the differential interference contrast. Images
were registered with ×40, NA-1.4 oil immersion objective using Leica
DFC360FX CCD camera under the control of the Leica Application
Suite X software.35
2.3 | Cell motility and invasion assays
The cells were seeded into 12-well plates at a density of 5 × 103
cells/cm2 (short-term incubation variant) or 5 × 102 cells/cm2 (long-
term incubation variant). Cell movement was recorded for 6 hours at
300 seconds time intervals (using a dry ×10, NA-0.75 objective) with
a time-lapse Leica DMI6000B video-microscopy system equipped
with the temperature chamber (37C ± 0.2C/5% CO2), IMC contrast
optics and a DFC360FX CCD camera. Single cell trajectories were
constructed from the sequences of cell centroid positions to estimate
the total lengths of single cell trajectories (distance [μm]), total lengths
of single cell displacements (displacement [μm]), speed of cell move-
ment (speed: distance/recording time [μm/h]) and speed of cell dis-
placement (displacement/recording time [μm/h]). Single cell
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parameters were further compiled to calculate the averaged values of
the parameters at the population level (from >3 independent experi-
ments; number of cells >50).36 For transmigration assays, cells
(2 × 103) were seeded on the upper side of transwell inserts in
24-well plates, allowed to transmigrate in chemodynamic conditions
for 48 hours, fixed with 3.7% formaldehyde and stained in a 0.2%
solution of Coomassie brilliant blue R250 in methanol:acetic acid:
water (46.5:7:46,5; [v/v/v]) for 1 hour. Areas of cell colonies were
further estimated with Leica DMI6000B system.
2.4 | Proliferation and apoptosis assays
Cells were seeded into 24-well plates (Corning) at the density of
5 × 103 cells/cm2, cultivated in the standard medium for 24 hours,
before the administration of the media containing DCX and/or
FF. After 48 hours, the cells were harvested, resuspended in the origi-
nal culture medium and counted with a Coulter Z2 Counter (Beckman
Coulter Inc, Fullerton, California). For the quantification of apoptosis,
cells were dissociated, resuspended in original medium and stained
with AnnexinV/propidium iodide according to manufacturer's protocol
(BD Pharmingen, San Diego, California). Flow cytometric detection
of apoptotic cells was performed with a ImageStreamX system
(Amnis).22 At least 5 × 104 cells were analyzed for each condition.
2.5 | Clonogenic potential of SCL progenies
SCL-derived cells were seeded at the density of 5000 cells/cm2. After
reaching the confluence (usually 48 hours), their progeny was trypsinized
and seeded into 6-well dishes (Corning) at the density of 500/cm2. Then,
the cells were allowed to develop the clones for the next 72 hours in the
absence/presence of DCX and/or FF, fixed with 3.7% formaldehyde, and
stained in a 0.2% solution of Coomassie brilliant blue R250 in methanol:
acetic acid:water (46.5:7:46,5; [v/v/v]) for 1 hour. After washing in dis-
tilled water, the numbers of cell colonies/well were assessed with Leica
DMI6000B microscope in the bright-field mode.
2.6 | In vivo analyses
Severe combined immunodeficient (SCID) mice (age: ca. 5 weeks;
Charles River Laboratories) were maintained in a temperature-con-
trolled, pathogen-free room, in community cages on a standard labo-
ratory diet with free access to drinking water and a 12 hour day/night
regime. Before the experiments, the animals were subjected to the
quarantine and acclimatized for at least 2 weeks. Cancer cells were
mixed with BD Matrigel Basement Membrane Matrix High Concentra-
tion (1:1 in PBS; BD Biosciences), and 40 μL of the cold suspension
(1.5 × 105 cells) was subcutaneously injected into abdominal flank of
SCID mice. DCX (10 or 20 mg/kg) was administered intraperitoneally
every 6 or 4 days, respectively, whereas FF (60 mg/kg) was adminis-
tered intragastrically every day or 2 days for both DCX schemes. The
mice were observed for 2 to 4 weeks for the appearance and develop-
ment of tumors. Volumes of developing tumors were calculated
according to the following formula: V = (Π/6)a × b × c, where a, b, and
c are perpendicular diameters of the ellipsoid approximating the shape
of the tumor. Afterward, the animals were sacrificed and the tumor
biopsies subjected to sectioning and to immunohistochemical CD44
staining. Animals were handled according to the protocols and guide-
lines approved by the 2nd Local Ethics Committee for Experiments on
Animals at the Jagiellonian University in Cracow (Dec. No. 290/2017).
2.7 | Calcein efflux assay
Cells were seeded into 12-well plates at a density of 5 × 103 cel-
ls/cm2, cultivated for 24 hours and immersed in culture medium sup-
plemented with 0.25 μM calceinAM (Life Technologies, Carlsbad,
California, C3099) for 30 minutes at 37C. Then, the cells were rinsed
and the sequences of fluorescence images of at least 16 randomly
chosen confluent culture regions were collected in green channel (A4;
GFP excitation - BP470/40; emission - BP525/50) 5 and 30 minutes
after calcein AM administration. In each experiment, the stacks were
obtained with the same excitation/exposure settings (excitation/cam-
era gain/time of exposition). Efflux Index was estimated for each stack
with LasX software (Leica) and calculated for each specimen.22
2.8 | Statistical analysis
All data were expressed as mean ± SEM from at least three indepen-
dent experiments (N > 3). The statistical significance was tested with
t-Student test or one-way ANOVA followed by post hoc Tukey's com-
parison for variables with non-normal (tested with Levene's compari-
son) and normal distribution, respectively. Statistical significance was
shown at P < .05.
3 | RESULTS
3.1 | CD133+/−/CD44+/− cancer SCL cells display
enhanced drug resistance
CD133 and CD44 have previously been identified as the markers of
prostate CSCs.13,33 Flow-cytometric analyses revealed very small
(<0.05%) subpopulations of CD133+, CD133+/CD44+, and of CD44+
cells in DU145 populations (Figure 1A). Their abundance remained
stable during the long term propagation of the cell line. Furthermore,
these SCL cells displayed a relatively high resistance to DCX, as illus-
trated by their more abundant fractions in DCX-exposed populations
(>0.2%). In the presence of serum (FBS), naive and DCX-treated
CD44+ cells progressively acquired CD133−/CD44− phenotype
in vitro, which indicates that they display the potential corresponding
to CSCs in vivo. Due to the considerable plating efficiency of their
direct progenies (Figure 1B), SCL cells finally gave rise to CD133−/
1547
CD44− lineages of proliferating “bulk” cells (nSCL_DU145 and
dcxSCL_DU145, respectively; Figure 1C). These lineages (in particular,
dcxSCL_DU145 cells) displayed slightly more abundant stress fibers
and matured focal adhesions than their naive counterparts. Concomi-
tantly, slightly lower proliferation and motility rates were seen in both
SCL progenies in control conditions (Figure 1D). They were accompa-
nied by their increased resistance to DCX, illustrated by relatively high
motility and proliferation rates (Figure 1E), and a low apoptosis ratio
of nSCL_DU145 and dcxSCL_DU145 cells cultivated under DCX
stress (Figure 1F; cf. Figure S1). Corresponding potential was dis-
played by CD44+PC3 SCL and CD133+DU145 SCL cells, as illustrated
by increased DCX-resistance of DCX-treated SCL progenies
(Figures S2 and S3, respectively; see Supplementary Material). Thus,
CD44+ SCLs and the selective expansion of their CD44− progenies
may lead to the formation drug-resistant cell lineages in vitro.
3.2 | CD44+ cells underlie DCX-induced
microevolution of prostate cancer drug resistance
To further confirm the involvement of SCLs in the microevolution of
drug resistance, we subjected DU145 cells to the long term DCX
treatment in vivo and in vitro. In vivo analyses revealed a DCX-
induced temporary arrest of DU145 tumor growth, followed by its
apparent recovery (Figure 2A). This complex response indicates a grad-
ual adaptation of prostate cancer cells to DCX. To trace this adaptation
process in vitro, we intermittently exposed DU145 cells to DCX
administered at increasing concentrations.22 Thus, the microevolution
of drug-resistant DU145 lineages was induced (DU145_DCX20 and
DU_DCX50). They displayed considerably higher DCX-resistance than
dcxSCL_DU145 cells, as illustrated by negligible DCX effects on their
motility and proliferation (Figure 2B). FACS analyses revealed relatively
F IGURE 1 Docetaxel (DCX)-resistance and differentiation potential of DU145 stem cell-like (SCL) CD44+ cells. A, Abundance of CD133+/
CD44+ SCL cells in DU145_DCX20 and DU145_DCX50 populations (calculated as % of total cell number) in the absence/presence of DCX
(10 nM). The values in compensated dot-plots represent relative SCL fractions (N = 50 000). B, Clonogenic activity of CD44+ SCL progenies (500/
cm2) estimated with CBB R250 staining. Scale bar = 2 mm. C, nSCL_DU145 and dcxSCL_DU145 cells were cultivated for 2-6 passages and their
morphology/actin cytoskeleton architecture was estimated with fluorescence microscopy. Scale bar = 50 μm. D-F, The effect of 10 nM DCX on
the motility (D, E; left), proliferation (D, E; right) and apoptosis (F) of nSCL_DU145 and dcxSCL_DU145 cells estimated with time-lapse
videomicroscopy (after 6 hours), Coulter counter (after 48 hours), and FACS (after 72 hours), respectively. Cell trajectories are depicted in circular
diagrams (axis scale in μm) drawn with the initial point of each trajectory placed at the origin of the plot (registered for 6 hours; N > 50). Dot-plots
and column charts show movement parameters at the single cell and population level, respectively (plotted as % of control). Apoptosis was
assessed in 50 000 AnnexinV/PI-stained cells. The statistical significance of the differences was tested with t-Student test (A, B, F and
proliferation in D, E; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild-type [WT] lineage; sP ≤ .05 vs indicated bars) or by one-way ANOVA followed
by post hoc Tukey's HSD (D, E motility; *P ≤ .05 vs WT lineage). All results are representative of a least three independent experiments (N ≥ 3).
Note the drug resistance of CD44+ SCL cells and their ability to differentiate into DCX-resistant “bulk” lineages
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ample CD44+ cells in DU145_DCX20 and DU_DCX50 populations
(Figure 2C). Again, their abundance remained stable during the long
term propagation of the cell line. DCX (10 nM) treatment had a minute
effect on the abundance of SCLs in these lineages and on their plating
efficiency (Figure 2D). The lineages derived from DU145_DCX20 SCL
cells in the absence/presence of DCX (nSCL_DU145_DCX20 and
dcxSCL_DU145_DCX20 cells, respectively) displayed a phenotype
corresponding to “maternal” cells, that is, a stable nonpolarized mor-
phology (not shown), paralleled by slightly lower proliferation and motil-
ity rates (Figure 2E). Their response to 10 nM DCX was similar to that
of maternal cells, whereas SCL progenies showed less pronounced apo-
ptotic response to DCX treatment (Figure 2F). This was correlated with
the high efficiency of efflux systems as illustrated by calcein efflux
assays (Figure 2G). Corresponding reactions to DCX were observed in
the progenies of CD44+ PC3_DCX20 cells, which retained very high
DCX resistance (Figure S4), whereas the progenies of CD133+
DU145_DCX20 cells were less drug resistant than their CD44+-derived
counterparts (Figure S5). Thus, we confirmed the relevance of DCX-
induced clonal SCL expansion for the microevolution of prostate cancer
drug-resistance in vitro and in vivo.
F IGURE 2 CD44+ stem cell-like (SCL) cells participate in the microevolution of prostate cancer drug-resistance in vitro and in vivo. A, DU145
cells were subcutaneously injected into abdominal flank of Severe Combined ImmunoDeficiency (SCID) mice and tumors growth was estimated
for 2 to 4 weeks in the presence/absence of docetaxel (injected at 20 mg/kg b.w.). At least 10 animals were taken for each variant (N > 10). Scale
bar = 250 μm. B, Effect of docetaxel (DCX) on the motility and proliferation of DU145_DCX20 and DU145_DCX50 cells estimated after 6 and
48 hours of incubation, respectively. Dotted line illustrates the data for wtDU145 cells. C, The abundance of CD133+/CD44+ SCL cells in DCX
(10 nM)-treated DU145_DCX20 and DU145_DCX50 populations (calculated as % of total cell number). D, Clonogenic potential of CD44+ SCL
cell progenies (cf. Figure 1B; dotted line = wtDU145 cells). E, Effect of 10 nM DCX on motility (left) and proliferation (right) of nSCL_and dcxSCL-
derived lineages of DU145_DCX20 and DU145_DCX50 cells. F, Cellular apoptotic response to 10 nM DCX estimated with AnnexinV/PI assay.
G, Calcein efflux intensity in nSCL_and dcxSCL_DU145 populations. Scale bar = 200 μm. The statistical significance of the differences was tested
with t-Student test (A, C, D, F, G and proliferation in B, E; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild-type [WT] lineage or selected bars) or by
one-way ANOVA followed by post hoc Tukey's HSD (A and motility in B, E; #P ≤ .05 vs untreated control; *P ≤ .05 vs WT lineage (or selected
bars/points). All results are representative of a least three independent experiments (N ≥ 3). Note the microevolution of prostate cancer drug
resistance under DCX stress in vivo and in vitro
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3.3 | Fenofibrate impairs drug resistance of CD44+
SCL cell offspring
We have previously shown the interference of FF with the drug resis-
tance of prostate cancer cells.22 Analyses of the cytostatic effects of
combined DCX/FF treatment on the progenies of CD44+ SCL cells
demonstrated the attenuating effect of FF on their DCX-resistance
(Figure 3A). This is illustrated by the inhibition of DU145,
nSCL_DU145, and dcxSCL_DU145 cell motility immediately after
DCX/FF administration. Corresponding effects were seen in the
populations of DU145_DCX20, nSCL_DCX20, dcxSCL_DCX20 cells.
These responses were followed by impairment of their clonal efficiency
(Figure S6), the retardation of cell proliferation (Figure 3B, cf. Figure 2E
for DCX activity) and accompanied by the decomposition of
microtubular cytoskeleton, which apparently results from the impaired
activity of efflux systems in the analyzed cells (Figure 3C). The cells that
survived long term (48 hours) combined DCX/FF treatment displayed
nonpolarized morphology, disrupted cytoskeleton, and relatively low
motility (Figure 3D). Similar DCX/FF activity was observed in the
populations derived from CD44+ DU145_DCX50 SCL cells (Figure S7),
CD133+ DU145 SCL cells (Figure S8A), and from CD44+ PC3 SCL cells
(Figure S8B). On the other hand, we also observed less pronounced
reactions of nSCL and dcxSCL cells to the combined DCX/FF treatment
(cf. Figure 3D; Figure S8), which were accompanied by their diminished
apoptotic response (cf. Figure 3E). These observations show that DCX-
directed clonal expansion of SCL cells does not prompt the microevolu-
tion of DCX/FF resistance; however DCX-resistant cells can partly
adapt to the combined DCX/FF treatment.
F IGURE 3 Stem cell-like (SCL) cell derived DU145 lineages display sensitivity to the combined docetaxel/fenofibrate (DCX/FF) treatment. A,
Motility of naïve DU145 and DU145_DCX20 cells, and their counterparts derived from naive and DCX-treated SCL cells (nSCL_ and dcxSCL,
respectively) was estimated with time-lapse videomicroscopy immediately after the administration of DCX and/or FF (10 nM/25 μM). B, Cells
were treated with DCX and/or FF as in A and counted with Coulter counter after 48 hours. C, The architecture of microtubular cytoskeleton was
estimated with immunofluorescence after 48 hours of DCX/FF treatment along with calcein efflux assay (lower panel; cf. Figure 1G). D, Cells
were treated with DCX/FF for 48 hours and their morphology/actin cytoskeleton architecture was visualized with immunofluorescence. Time-
lapse videomicroscopy was employed to assess long-term (48 hours) effects of FF, DCX and DCX/FF on cell motility (lower panel). E, Cells were
DCX/FF treated for 72 hours and their apoptotic response was estimated by annexinV/PI assay. Compensated dot-plots comprise 30 000/50
000 events, classified based on their bright-field ratios and/or nuclear contrast. Scale bars = 50 μm. D, The statistical significance of the
differences was tested with t-Student test (B, C, E; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild-type [WT] lineage or selected bars) or by one-
way ANOVA followed by post hoc Tukey's HSD (A, D; *P ≤ .05 vs WT lineage or selected bars/points). Note the sensitivity of SCL-derived
lineages to the combined DCX/FF-treatment
1550 WRÓBEL ET AL.
3.4 | SCL cells are resistant to the combined DCX/
FF treatment
Further analyses were performed to address the mechanisms
underlying cell adaptation to the combined DCX/FF stress. The
role of SCL cells in this process is indicated by their increased
numbers in DCX/FF-treated DU145 populations (Figure 4A). Flow
cytometric studies revealed considerably increased fractions of
CD133+, CD133+/CD44+, and CD44+ cells in DCX/FF-treated
DU145 (0.82% vs 0.011% in DCX-treated variant) and PC3
populations (Figure S9A). Furthermore, the appearance of
poly(morpho)nuclear giant cells (PGCs; Figure 4B) and the expres-
sion profile of multipotency markers in DCX/FF-treated
populations of DU145 cells revealed the interrelations between
DCX/FF-activated PGCs and the generation of SCL cells. In partic-
ular, CD44+ expression was observed in PGCs (Figure 4C). Con-
comitantly, scattered Nanog+ and Oct+ cells were seen in DCX/
FF-treated DU145 specimens. Less prominent, although signifi-
cant increase of SCL fraction was also observed in DCX/FF-
treated populations of DU145_DCX20 and DU145_DCX50 cells
(Figure 4A). It was accompanied by a less prominent induction of
PGC phenotype22 and by a higher clonogenic potential of
DU145_DCX20/50 SCL cells than of their wild-type counterparts
(Figure 4D). These observations confirm the activation of a self-
defense system(s) in prostate cancer cell populations in response
to the DCX/FF stress. It leads to the formation of DCX/FF-resis-
tant CD44+ SCL cell population via stress-induced activation
of PGCs.
3.5 | Progeny of DCX/FF-resistant SCL cells
display relatively high resistance to DCX
In an attempt to further assess the consequences of DCX/FF treatment
for SCL cells' potential, we focused on the “bulk” progeny of DCX/FF-
treated SCL cells (dcx/ffSCL_DU145 and dcx/ffSCL_DCX20) in vitro
and in vivo. They displayed remarkable DCX-resistance, while
remaining sensitive to the combined DCX/FF treatment. This is illus-
trated by the inhibition of their motility (Figure 5A), proliferation
(Figure 5B), and by the induction of their apoptosis under DCX/FF
stress. Concomitant disorganization of microtubular cytoskeleton
(Figure 5C) could be ascribed to the FF-induced inhibition of P-gp,22 as
also determined for DU145wt and DU145_DCX20 cells (cf. Figure 3B).
In vivo assays revealed the initial growth arrest of DCX/FF-treated
DU145_DCX20 tumors, accompanied by the presence of CD44+ cells,
and followed by tumor growth recovery from DCX/FF stress
(Figure 5D). Concomitantly, the attenuation of dcx/ffSCL_DU145 and
dcx/ffSCL_DCX20 cell invasiveness under DCX/FF stress (Figure 5E)
was paralleled by their epithelioid phenotype, low proliferation and
motility in DCX/FFlow conditions (Figure 5F). Thus, these cells are
predestined to form the local barriers that potentially reduce the
intratumor bioavailability of DCX/FF. Together with the increased
DCX-resistance of dcx/ffSCL_DCX20 cells (Figure 5B; cf. Figure 2E),
this may account for the discrepancy between cell DCX/FF-sensitivity
in vitro and tumor growth recovery in vivo. Along with the
corresponding data on CD44+ PC3 and CD133+ DU145 cells (Fig-
ure S9), our observations confirm the role of CD44+/CD133+cells as a
“reservoir” of drug resistance. Phenotypic reprogramming and restricted
F IGURE 4 Docetaxel/fenofibrate (DCX/FF)-treatment activates the generation of PGCs. A, FACS analyses of the abundance of CD133+ and/
or CD44+ cells in the populations of wild-type and DCX-resistant DU145 lineages under DCX/FF stress. Compensated dot-plots comprise
50 000 events, classified based on their bright-field ratios and nuclear contrast. The values in the plots represent relative stem cell-like (SCL)
fractions. Dotted lines in bar plot illustrate SCL percentages in control (100%) and after DCX treatment. B, DU145 cells were cultivated in the
presence of DCX/FF for 48 hours, stained against vinculin (green), F-actin (red), and DNA (blue) to show polymorphonuclear cells. C, Cells were
treated as in B, followed by their staining against CD44, Oct3/4, Nanog and CD44, and polymorphonuclear cells were vizualized with
fluorescence microscopy. Scale bars = 50 μm. D, Clonogenic potential of CD44+ SCL cells derived from wild-type and DCX-resistant DU145
populations cultivated in the presence of DCX/FF. Horizontal lines above bars represent plating values upon DCX treatment. Scale bar = 2 mm.
The statistical significance of the differences was tested with t-Student test (A, D; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild-type
[WT] lineage[s] or selected bars). All results are representative of a least three independent experiments (N ≥ 3). Note the increased fraction of
PGCs and the abundance of CD44+ cells in DCX/FF-treated cell populations
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DCX/FF bioavailability may facilitate the adaptation of prostate tumors
to the combined DCX/FF stress.
3.6 | DCX/FF-induced phenotypic microevolution
increases cell malignancy
Furthermore, we focused on the effect of limited DCX/FF bioavail-
ability on the phenotype of drug-resistant cells. Long term
propagation (>30 passages, 1:8) of the progenies of naive and
DCX/FF-treated CD44+ cells in the absence of both agents enabled
us to establish DU145 lineages, characterized by reduced resistance
to DCX (Figure 6A). For instance, the proliferation of dfSCL_DCX20/
LT cells in the presence of 5 nM DCX was ca. twofold slower than
that of dfSCL_DCX20 cells. Attenuated growth and viability of
dfSCL_DCX20/LT cells in the presence of DCX was accompanied by
the decreased activity of drug-efflux systems (Figure 6B) and
increased invasive potential of LT cells. This is illustrated by their
F IGURE 5 DU145 stem cell-like (SCL) cells generate docetaxel/fenofibrate (DCX/FF)-sensitive offspring. A,B, dcx/ffSCL_DU145 and
dcx/ffSCL_DCX20 cells were cultivated in the presence of DCX and/or FF (10 nM/25 μM). Their motility (A), proliferation, and apoptotic
response (B) was quantified after 6, 48 and 72 hours, respectively. C, Cells were cultivated as in A and the architecture of microtubular
cytoskeleton was estimated after 48 hours of in DCX/FF treatment. Scale bar = 50 μm. D, DU145_DCX20 cells were subcutaneously injected
into abdominal flank of Severe Combined ImmunoDeficiency (SCID) mice and the growth of tumors was estimated for 2 to 4 weeks in the
presence/absence of DCX (10 mg/kg) and FF (60 mg/kg). At least 10 animals were taken for each variant (N > 10). E, The morphology and
displacement of dfSCL_DU145 and _DCX20 cells quantified after 48 hours of DCX or DCX/FF treatment. Scale bar = 50 μm. F, Doubling times
and motility rates of naïve DU145 cell lineages and their SCL counterparts. The statistical significance of the differences was tested with t-
Student test (D and proliferation in B, F; #P ≤ .05 vs untreated control; *P ≤ .05 vs wild-type [WT] lineage(s) or selected bars, or by one-way
ANOVA followed by post hoc Tukey's HSD (A and motility in B, E, F; *P ≤ .05 vs WT lineage(s); #P ≤ .05 vs untreated control). All results are
representative of a least three independent experiments (N ≥ 3). Note the increased DCX-resistance and slightly reduced sensitivity of
dfSCL_DU145 lineages to the combined DCX/FF treatment
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increased motility in control conditions (Figure 6C) and their increased
capability of penetrating Matrigel-coated microporous membranes
(Figure 6D). Concomitantly, we observed increased fractions of Snail-
1high dfSCL_DCX20/LT cells in comparison to their drug-resistant coun-
terparts (Figure 6E). Together with their rear-front polarized, invasive
morphology (characteristic for post-epithelial-mesenchymal transition
[EMT] cells; Figure 6F), they confirm that the limited DCX/FF bioavail-
ability can prompt the reversed microevolution of drug-resistant cell lin-
eages toward the expansive phenotype. This notion was further
substantiated by relatively weak effects of the combined DCX/FF
treatment on the invasiveness of dfSCL_DCX20/LT cells (Figure 6G).
Thus, the oscillations of intratumoral DCX/FF bioavailability may occa-
sionally facilitate the microevolution of DCX/FF-resistant prostate can-
cer cell lineages. However, this effect should not be overestimated as
other DCX-resistant and DCX-sensitive DU145_SCL progenies retained
sensitivity to the combined DCX/FF treatment (Figure 6G).
4 | DISCUSSION
“Clonal evolution of cancer stem cells” is believed to determine stress-
induced cancer microevolution.18,37 Drug-resistance, self-renewal
F IGURE 6 Reversed microevolution of drug-resistant DU145 cells increases their invasive potential. A, Proliferation of SCL-derived DU145
lineages (ST) and their (LT) counterparts estimated after 48 hour-long docetaxel (DCX) treatment. B, Calcein efflux intensity in dfSCL_DU145/LT
and dfSCL_DU145_DCX20/LT in comparison to their ST counterparts (indicated by dotted lines/arrows). Scale bar = 200 μm. C, Motility of
dfSCL_DU145/LT and dfSCL_DU145_DCX20/LT measured as % of ST control. D, Transmigration of dfSCL_DU145/LT and
dfSCL_DU145_DCX20/LT cells through microporous membranes. Scale bar = 2 mm. E, Relative fractions of Snail1-/E-cadherinhigh cells in
dfSCL_DU145_DCX20/LT populations quantified with ImageStream. F, Morphology of DCX/fenofibrate (FF)-treated dfSCL_DU145/LT and
dfSCL_DU145_DCX20/LT cells. Scale bar = 50 μm. G, Effect of DCX and/or FF on the proliferation (upper panel) and displacement (lower panel)
of LT DU145 and DU145_DCX20 lineages. All results are representative of a least three independent experiments (N ≥ 3). The statistical
significance of the differences was tested with t-Student test (A, B, D; #P ≤ .05 vs untreated control; *P ≤ .05 vs ST lineage or selected bars/
points) or by one-way ANOVA followed by post hoc Tukey's HSD (C, G; *P ≤ .05 vs wild-type [WT] lineage or selected bars/points). Note the
increased invasiveness of drug-sensitive/Snail-1high cells undergone reversed microevolution under the limited DCX/FF bioavailability
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capacity, and multipotency of CSCs underlie their survival under che-
motherapeutic stress in vivo and the selective expansion of their
stress-resistant progenies.5,7 Interference of FF with prostate cancer
drug-resistance22 suggests its potential application in metronomic
therapies of prostate tumors. Following these facts, we focused on
the reactions of CD44+ SCL cells to the combined DCX/FF treatment
and on their involvement in DCX/FF-induced prostate cancer micro-
evolution. We further traced the consequences of DCX/FF-induced
selective expansion of CD44+ SCL cells and their differentiation into
hyper-resistant “bulk” progenies. In particular, we addressed SCL cell
involvement in the adaptation of cell populations to the combined
DCX/FF treatment in vitro and in vivo. These studies confirmed that
FF can be applied for the treatment of drug-resistant prostate
tumors.22 However, they also revealed the transitions between
CD44+ SCL and CD44− phenotype, which maintain phenotypic
“steady-state” of prostate cancer cell populations. FF amplifies the
expansion of hyper-resistant CD44+ SCL cells and their progenies, lim-
iting the effectiveness of FF-based treatment strategies.
Prostate cancer CD44+ SCL cells are commonly observed in vitro.
In serum-free conditions their differentiation is inhibited, which pet-
rifies their “primitive” phenotype.32,38 We observed the persistence of
CD44+/Nanog+/Oct-4+ DU145/PC3 cells during the long term propa-
gation of prostate cancer cells, accompanied by the differentiation of
CD44+ SCL cells toward CD44− phenotype(s). These observations
suggest a continuous self-renewal of CD44+ cells in the presence of
serum. It can occur through symmetric divisions of CD44+ SCL cells
and/or through asymmetric divisions of “retro-differentiating” CD44−
“bulk” cells. Apparently, bidirectional transitions between CD44+ and
CD44− phenotype maintain the phenotypic “steady-state” of hetero-
geneous prostate cancer cell populations. These transitions also deter-
mine the selective expansion of drug-resistant prostate cancer cell
sub-populations under the chemotherapeutic stress. Their involve-
ment in the microevolution of drug-resistance and the role of CD44+
cells as a “reservoir” of drug resistance13,14 is illustrated by their
increased fractions observable in DCX-treated DU145 and PC3
populations and increased drug resistance of their progenies. CD133+
cells may play a corresponding role. However, differences in the reac-
tivity of CD44+ and CD133+ cell progenies to DCX/FF (generally
lower resistance of CD133+-derived cells) prompt questions whether
they represent a discrete subpopulation or are interspersed with
CD44+ population(s).39
Analyses of DU145 and PC3 reactions to the combined DCX/FF
treatment confirmed the potential of FF for the treatment of drug-
resistant prostate tumors. It is illustrated by cytostatic and pro-
apoptotic effects that we observed in DCX/FF-treated “bulk” (CD44−)
progenies of naive and DCX-induced SCL cells. Notably, CD44+ SCL
cells remained resistant to the combined chemotherapeutic/metabolic
stress; however it prompted their differentiation toward “hyper-resis-
tant” phenotype(s). This finding reveals the adaptation/survival strat-
egy, which potentially prompts the microevolution of prostate tumor
drug resistance. Several lines of evidence indicate the involvement of
poly(morpho)nuclear cells (PGCs) in this process. First, PGCs are
known to act as cellular “spores” that survive the microenvironmental
cataclysm and give rise to CSCs.40-42 Then, increased fractions of
polyploid PGCs cells in DCX/FF-treated cell populations (8.9% in com-
parison to 0.8% in control)22 correlated with the abundance of SCL
cells. This correlation was accompanied by the presence of CD44 in
DCX/FF-induced PGCs. The origins of PGCs, in particular the involve-
ment of big mononuclear (diploid) cells in their generation, and the
budding of SCL cells from PGCs remains to be directly confirmed. Fur-
ther transcriptomic, proteomic and lipidomic analyses of PGCs and
SCL cells should also help to define PGC/SCL phenotype in the
absence/presence of chemotherapeutic/metabolic stress. They are
necessary to elucidate whether chemotherapy-induced development
of drug resistance follows strictly a CSC program.18,31 However, our
findings collectively reveal DCX/FF-induced acquisition of PGC phe-
notype by the “bulk” cells and indicate the potential role of PGCs in
SCL cell generation. DCX/FF-induced activation of this sequence
apparently facilitates chemotherapeutic/metabolic stress-induced
microevolution of prostate cancer drug resistance.
Biological significance of these events was confirmed by our in vivo
data. Inhibitory effect of DCX on the growth of wild-type DU145
tumors, followed by their recovery after the initial DCX-induced arrest,
can be explained by the microevolution of DCX-resistance in DU145
populations. Somewhat surprising recovery of wild-type and drug-
resistant DU145 tumors observed in the presence of DCX/FF can be
explained by the evolution of cellular hyper-resistance to DCX. Concomi-
tant dormancy, immobility and epithelioid phenotype of super-resistant
cells facilitates the formation of DCX/FFlow tumor compartments. When
subsequently colonized by “hyper-resistant” CD44+/CD133+ cells, these
compartments may further promote the growth of tumors under chemo-
therapeutic/metabolic stress. Additionally, DCX/FF may selectively pro-
mote/impair the expansion of discrete cell lineages within
heterogeneous mass of tumor cells. In our hands, lineage-specificity of
DCX/FF resistance was illustrated by relatively low clonal capacity of the
direct CD44+ PC3 progenies under DCX/FF stress, accompanied by their
considerable invasive potential after prolonged expansion. Reversed
microevolution of drug-sensitive SCL/“bulk” cells induced by low
DCX/FF bioavailability may further participate in this process, as indi-
cated by the signs of EMT in DU145 populations after long term cultiva-
tion in the absence of DCX/FF. Thus, the synergy of cytostatic, anti-
invasive, and pro-apoptotic DCX/FF effects in vitro confirm the potential
of the metabolic chemotherapy for palliative treatment of drug-resistant
prostate tumors. However, the adaptation of prostate tumors to meta-
bolic stress may counteract this effect, determining tumor recovery from
the combined DCX/FF stress in vivo.22,30
Collectively, our data indicate that bidirectional transitions
between metastable CD44− “bulk” and CD44+/CD133+ SCL pheno-
type maintain the phenotypic “steady-state” of heterogeneous pros-
tate cancer cell populations and their microevolution toward
microenvironmentally favorable phenotypes. Accordingly, chemother-
apeutic stress biases phenotypic “steady-state” of prostate cancer cell
populations toward the generation of increasingly drug-resistant
CD44+ cells by their increasingly drug-resistant CD44− progenies.
Combined DCX/FF stress amplifies this effect by inducing the adapta-
tion responses of CD44− bulk cells. Apart from growth retardation
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and autophagy,43,44 they include the formation of PGCs,40 which
apparently generate CD44+ SCL cells that initiate the expansion of
super-resistant CD44− cell lineages. Concomitant reconstitution of
intratumoral barriers (potentially limiting DCX/FF bioavailability in
intratumoral niches) prompts the reverse microevolution of resident
cells toward more invasive post-EMT phenotype. Thus, also the tran-
sitions between mesenchymal and epithelioid phenotype can partici-
pate in a progressive prostate tumor adaptation to the combined
chemotherapeutic/metabolic stress in vivo.45,46 The mechanisms
underlying PGC generation, mesenchymal-epithelial transition/EMT-
related adaptation processes, interrelations between CD44+ and
CD133+ phenotypes and their relation to the “true” CSC phenotype
require further research. However, we provide the evidence for the
cooperation of CD44+/CD133+ cells and their clonally expanding
progenies in the prostate tumor adaptation to the chemotherapeutic/
metabolic stress, hampering the effectiveness of prostate cancer
treatment.
5 | CONCLUSION
Our study confirms the potential of FF for the treatment of drug-
resistant prostate tumors. This agent apparently reduces effective
doses of chemotherapeutics via the interference with the drug-
resistance systems in prostate cancer cells, thus being the potential
tool to improve the living standard of prostate cancer patients. How-
ever, we also reveal the limitations of metronomic prostate cancer
treatment strategies. Interference of FF with the transitions between
CD44+ SCL and CD44− phenotype affects phenotypic “steady-state”
of prostate cancer cell populations and biases their microevolution
toward drug-resistant phenotype. This activity can petrify/augment
tumor drug-resistance and prompt cancer relapse via allowing super-
resistant cells to repopulate old “niches” and reconstitute the tumor in
its “hyper-resistant” form. Thus, the adaptation responses of prostate
cancer cells to FF-induced metabolic stress can progressively reduce
the efficiency of combined DCX/FF application in the palliative ther-
apy of prostate cancer. This stresses the need for the comprehensive
look on the functions of CSCs in prostate cancer drug resistance and
for a more thorough elucidation of side effects and restrictions
of metronomic anticancer strategies as the leading challenges of the
current oncology.
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